Samina Reza is an Oncology physician. OpenAlex indexes 6 publications with 237 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
38135 Market Sq
Zephyrhills, FL 335427505
Telephone
813-780-2642Provider last certified this registry record 27 Aug 2021.
Industry payments
49 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year20255 payments
- Regeneron Healthcare Solutions, Inc.Program year20253 payments
- Novartis Pharmaceuticals CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
88.3%Erythropoiesis-stimulating Agent86.9%Epoetin alfa99%Retacrit1%Procrit1%Part D + Part B<11 patientsFactor Xa inhibitor1.3%Xarelto57%Eliquis43%Part D≥13 patientsCancer & immunology
8.9%Aromatase Inhibitor3.8%Anastrozole80%Letrozole20%Part D≥56 patientsKinase inhibitor2.3%Imbruvica35%Jakafi21%Imatinib Mesylate14%Ibrance11%Calquence10%Kisqali9%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
2.4%Antidiarrheal microorganisms1.5%Folic Acid100%Part D≥33 patientsVitamin B120.8%Cyanocobalamin Injection100%Part D≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evidence for involvement of tumor necrosis factor‐α in apoptotic death of bone marrow cells in myelodysplastic syndromes
American Journal of Hematology
1999 - Sequential Activation of Caspase-1 and Caspase-3-like Proteases During Apoptosis in Myelodysplastic Syndromes
Stem Cells and Development
1999 - Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis
European Journal Of Haematology
1999 - Biologic Characteristics of 164 Patients with Myelodysplastic Syndromes
Leukemia & lymphoma/Leukemia and lymphoma
1999
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”